The new technology is a novel device designed to improve the delivery of progesterone medication. Administering doses of vaginal micronised progesterone is the NICE-recommended guideline for women who have suffered at least one prior miscarriage and subsequently face “threatened miscarriage”, the clinical term for when there is bleeding during early pregnancy. It’s estimated that over 150,000 women in the UK could be eligible for prescriptions of progesterone for threatened miscarriage each year. 

Progesterone is currently self-administered by patients via vaginal pessaries. This delivery method is prone to significant leakage, which can cause substantial anxiety and inconvenience for patients at an already distressing time.